Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Keyphrases

• Breast Cancer 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• I-SPY 100%
• Protein Drug 100%
• Drug Target 100%
• Chemotherapy Resistance 100%
• Chemotherapy Sensitivity 100%
• Phosphoprotein 100%
• Protein Signaling 100%
• Target Activation 100%
• Gene Expression 50%
• Multifunctional Protein 50%
• Androgen Receptor 50%
• Breast Cancer Patients 50%
• Protein Biomarkers 50%
• Triple-negative Breast Cancer 50%
• Mechanism of Action 50%
• Transcriptomics 50%
• Cyclin D1 (CCND1) 50%
• Expression Data 50%
• Molecular Subtypes 50%
• Molecular Landscape 50%
• Protein Activation 50%
• α1-adrenoceptor 50%
• Pathological Complete Response 50%
• Estrogen Receptor 1 (ESR1) 50%
• Non-response 50%
• Therapy Response 50%
• Quantitative Expression 50%
• Predictive Signature 50%
• Action-based 50%
• Fit-for-purpose 50%
• Response Prediction 50%
• HER2 Expression 50%
• DNA Repair Deficiency 50%
• Immune Checkpoint Therapy 50%
• Protein Pathway Activation Mapping 50%
• Global Resistance 50%
• Synergize 50%

Biochemistry, Genetics and Molecular Biology

• Signaling Protein 100%
• Phosphoprotein 100%
• Subtyping 50%
• Immune Checkpoints 50%
• Gene Expression 50%
• DNA Repair 50%
• Transcriptomics 50%
• Androgen Receptor 50%
• Cyclin D1 50%
• Estrogen Receptor Alpha 50%
• Deficiency 50%